North Point Portfolio Managers Corp OH Cuts Stock Position in Boston Scientific Corporation $BSX

North Point Portfolio Managers Corp OH reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 19.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 108,023 shares of the medical equipment provider’s stock after selling 26,202 shares during the quarter. North Point Portfolio Managers Corp OH’s holdings in Boston Scientific were worth $4,715,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific in the second quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific during the first quarter worth about $28,000. Rakuten Securities Inc. bought a new stake in shares of Boston Scientific in the second quarter worth about $30,000. Cassaday & Co Wealth Management LLC purchased a new position in Boston Scientific during the 1st quarter valued at about $32,000. Finally, Cetera Trust Company N.A bought a new position in Boston Scientific during the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.1%

Shares of BSX traded up $0.03 during trading hours on Wednesday, hitting $42.22. The company had a trading volume of 7,368,055 shares, compared to its average volume of 18,659,338. The firm has a fifty day moving average price of $46.81 and a 200-day moving average price of $51.11. Boston Scientific Corporation has a 52-week low of $41.81 and a 52-week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a market capitalization of $61.18 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 1.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, September 17th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $54.00 target price on shares of Boston Scientific in a research note on Saturday. Jefferies Financial Group reduced their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.31.

Insider Buying and Selling

In other news, CEO Michael Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Habiger bought 2,100 shares of the stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 194,522 shares of company stock valued at $9,385,210 over the last 90 days. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.